Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

Affiliations

• ¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrodon@mdanderson.org.
• ² Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• ³ University of Iowa, Iowa City, IA, USA.
• ⁴ Centro Integral Oncologico Clara Campal, Madrid, Spain.
• ⁵ Tohoku University Hospital, Sendai-Shi, Japan.
• ⁶ Institut Bergonié, Bordeaux, France.
• ⁷ Faculty of Medicine, University of Bordeaux, Bordeaux, France.
• ⁸ Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
• ⁹ Kanagawa Cancer Center, Yokohama, Japan.
• ¹⁰ Shizuoka Cancer Center, Shizuoka, Japan.
• ¹¹ Incyte International Biosciences Sàrl, Morges, Switzerland.
• ¹² Incyte Corporation, Wilmington, DE, USA.
• ¹³ Mass General Cancer Center, Harvard Medical School, Boston, MA, USA. lgoyal@stanford.edu.
• ¹⁴ Stanford Cancer Center, Stanford School of Medicine, Stanford, CA, USA. lgoyal@stanford.edu.